Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer
Authors
Keywords
-
Journal
ONCOGENE
Volume 33, Issue 2, Pages 148-156
Publisher
Springer Nature
Online
2012-12-18
DOI
10.1038/onc.2012.572
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- Dissecting the Heterogeneity of Triple-Negative Breast Cancer
- (2012) Otto Metzger-Filho et al. JOURNAL OF CLINICAL ONCOLOGY
- Predominance of mTORC1 over mTORC2 in the Regulation of Proliferation of Ovarian Cancer Cells: Therapeutic Implications
- (2012) Juan Carlos Montero et al. MOLECULAR CANCER THERAPEUTICS
- Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase
- (2011) Tingting Sun et al. CELL
- Targeted therapies for breast cancer
- (2011) Michaela J. Higgins et al. JOURNAL OF CLINICAL INVESTIGATION
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- Contagious Cancer
- (2011) J. S. Welsh ONCOLOGIST
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
- (2011) V. S. Rodrik-Outmezguine et al. Cancer Discovery
- Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
- (2010) Carlos H. Barrios et al. BREAST CANCER RESEARCH AND TREATMENT
- Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia
- (2010) F. Chiarini et al. CANCER RESEARCH
- Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells
- (2010) F. Hochgrafe et al. CANCER RESEARCH
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Multisite phosphorylation of Erk5 in mitosis
- (2010) E. DIaz-RodrIguez et al. JOURNAL OF CELL SCIENCE
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- Effect of Multikinase Inhibitors on Caspase-Independent Cell Death and DNA Damage in HER2-Overexpressing Breast Cancer Cells
- (2010) Samuel Seoane et al. JNCI-Journal of the National Cancer Institute
- Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
- (2010) Matthew R Janes et al. NATURE MEDICINE
- Preclinical development of molecular-targeted agents for cancer
- (2010) Alberto Ocana et al. Nature Reviews Clinical Oncology
- Triple-negative breast cancer: disease entity or title of convenience?
- (2010) Lisa Carey et al. Nature Reviews Clinical Oncology
- P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer
- (2010) J C Montero et al. ONCOGENE
- Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
- (2009) D. W. McMillin et al. CANCER RESEARCH
- In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
- (2009) K. P. Hoeflich et al. CLINICAL CANCER RESEARCH
- Tyrosine phosphorylation: thirty years and counting
- (2009) Tony Hunter CURRENT OPINION IN CELL BIOLOGY
- mTOR signaling at a glance
- (2009) M. Laplante et al. JOURNAL OF CELL SCIENCE
- Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR- : clinical activity and biological correlations
- (2008) M. Cristofanilli et al. ANNALS OF ONCOLOGY
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
- (2008) P. J.A. Eichhorn et al. CANCER RESEARCH
- The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma
- (2008) Philipp Baumann et al. EXPERIMENTAL CELL RESEARCH
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now